M B Effron
Overview
Explore the profile of M B Effron including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diodati J, Saucedo J, Cardillo T, Jakubowski J, Henneges C, Effron M, et al.
Thromb Haemost
. 2014 Apr;
112(2):311-22.
PMID: 24718367
High on-treatment platelet reactivity (HPR) has been identified as an independent risk factor for ischaemic events. The randomised, double-blind, TRIPLET trial included a pre-defined comparison of HPR in acute coronary...
2.
Kennedy J, Bymaster F, Schuh L, Calligaro D, Nomikos G, Felder C, et al.
Int J Geriatr Psychiatry
. 2001 Dec;
16 Suppl 1:S33-61.
PMID: 11748788
Objective: Olanzapine (OLZ) is unique among currently available antipsychotic medications in its antagonism of a range of receptor systems including dopamine, norepinephrine, serotonin, acetylcholine, and histamine. Olanzapine's mechanistic complexity provides...
3.
Tcheng J, Kereiakes D, Lincoff A, GEORGE B, Kleiman N, Sane D, et al.
Circulation
. 2001 Aug;
104(8):870-5.
PMID: 11514371
Background: Platelet glycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of percutaneous coronary intervention. This registry was conducted to characterize the effects of repeated administration of abciximab during...
4.
Lincoff A, LeNarz L, Despotis G, Smith P, Booth J, Raymond R, et al.
Ann Thorac Surg
. 2000 Sep;
70(2):516-26.
PMID: 10969673
Background: Abciximab during percutaneous coronary revascularization reduces ischemic complications, but concern exists regarding increased bleeding risk should emergency coronary surgical procedures be required. Methods: Outcomes were assessed among 85 patients...
5.
Kleiman N, Grazeiadei N, Maresh K, Taylor R, Frederick B, Lance E, et al.
Am Heart J
. 2000 Aug;
140(3):492-501.
PMID: 10966553
Background: We examined the ex vivo platelet aggregation profiles of patients who underwent percutaneous coronary intervention and received either abciximab, ticlopidine, or both agents. Study Design And Methods: The trial...
6.
Mak K, Effron M, Moliterno D
Drugs Aging
. 2000 May;
16(3):179-87.
PMID: 10803858
With increasing age of the general population, cardiovascular diseases are becoming a greater health burden. Coronary artery disease remains a major cause of morbidity and mortality worldwide. Among the various...
7.
Fredrickson B, Turner N, Kleiman N, Graziadei N, Maresh K, Mascelli M, et al.
Circulation
. 2000 Mar;
101(10):1122-9.
PMID: 10715258
Background: Abciximab and ticlopidine reduce adverse cardiovascular events after percutaneous transluminal coronary angioplasty (PTCA). The goal of the current study was to determine if combined abciximab/ticlopidine therapy inhibits arterial thrombosis...
8.
Makkar R, Goff B, Eigler N, Sebastian M, Fischell T, Barr L, et al.
Catheter Cardiovasc Interv
. 1999 Nov;
48(4):430-4.
PMID: 10559827
The efficacy of abciximab and moderate dose heparin in attaining reperfusion in acute MI was tested in a multicenter pilot study. Patients with acute MI of less than 6-hr onset...
9.
Brener S, Barr L, Burchenal J, Wolski K, Effron M, Topol E
Am J Cardiol
. 1999 Sep;
84(6):728-30, A8.
PMID: 10498145
We investigated the effect of platelet fibrinogen receptor blockade on infarct size after primary angioplasty. Abciximab significantly reduced the time-to-peak creatine kinase without affecting enzymatic infarct size, suggesting a beneficial...
10.
Tcheng J, Kereiakes D, Braden G, Jordan R, Mascelli M, Langrall M, et al.
Am Heart J
. 1999 Jul;
138(1 Pt 2):S33-8.
PMID: 10385789
Even with continued improvements in the technology of percutaneous coronary intervention (PCI), approximately 10% to 20% of patients undergoing PCI will require repeat procedures within 1 year. Furthermore, because of...